Rocchi P - Search Results

1

Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.

Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P, Paciencia-Gros M, Poizat F, Bentobji M, Azario-Cheillan F, Walz J, Salem N, Brunelle S, Moretta A, Olive D. Pasero C, et al. Among authors: rocchi p. Cancer Res. 2016 Apr 15;76(8):2153-65. doi: 10.1158/0008-5472.CAN-15-1965. Epub 2016 Apr 5. Cancer Res. 2016. PMID: 27197252

2

Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.

Rocchi P, Boudouresque F, Zamora AJ, Muracciole X, Lechevallier E, Martin PM, Ouafik L. Rocchi P, et al. Cancer Res. 2001 Feb 1;61(3):1196-206. Cancer Res. 2001. PMID: 11221851

3

Development of an ELISA detecting Tumor Protein 53-Induced Nuclear Protein 1 in serum of prostate cancer patients.

Saadi H, Seillier M, Sandi MJ, Peuget S, Kellenberger C, Gravis G, Dusetti NJ, Iovanna JL, Rocchi P, Amri M, Carrier A. Saadi H, et al. Among authors: rocchi p. Results Immunol. 2013 May 28;3:51-6. doi: 10.1016/j.rinim.2013.05.002. eCollection 2013. Results Immunol. 2013. PMID: 24600558 Free PMC article.

4

Targeted delivery of Dicer-substrate siRNAs using a dual targeting peptide decorated dendrimer delivery system.

Liu X, Liu C, Chen C, Bentobji M, Cheillan FA, Piana JT, Qu F, Rocchi P, Peng L. Liu X, et al. Among authors: rocchi p. Nanomedicine. 2014 Nov;10(8):1627-36. doi: 10.1016/j.nano.2014.05.008. Epub 2014 Jun 3. Nanomedicine. 2014. PMID: 24965758

5

Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.

Lelj-Garolla B, Kumano M, Beraldi E, Nappi L, Rocchi P, Ionescu DN, Fazli L, Zoubeidi A, Gleave ME. Lelj-Garolla B, et al. Among authors: rocchi p. Mol Cancer Ther. 2015 May;14(5):1107-16. doi: 10.1158/1535-7163.MCT-14-0866. Epub 2015 Mar 4. Mol Cancer Ther. 2015. PMID: 25740245

6

Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer.

Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, Salem N, Walz J, Moretta A, Olive D. Pasero C, et al. Among authors: rocchi p. Oncotarget. 2015 Jun 10;6(16):14360-73. doi: 10.18632/oncotarget.3965. Oncotarget. 2015. PMID: 25961317 Free PMC article.

7

The hallmarks of castration-resistant prostate cancers.

Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry de Villeneuve M, Rocchi P. Katsogiannou M, et al. Among authors: rocchi p. Cancer Treat Rev. 2015 Jul;41(7):588-97. doi: 10.1016/j.ctrv.2015.05.003. Epub 2015 May 9. Cancer Treat Rev. 2015. PMID: 25981454 Review.

8

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.

Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Rocchi P, et al. Cancer Res. 2004 Sep 15;64(18):6595-602. doi: 10.1158/0008-5472.CAN-03-3998. Cancer Res. 2004. PMID: 15374973

9

Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.

Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M. Rocchi P, et al. Cancer Res. 2005 Dec 1;65(23):11083-93. doi: 10.1158/0008-5472.CAN-05-1840. Cancer Res. 2005. PMID: 16322258

10

Active-targeted nanotherapy strategies for prostate cancer.

Katsogiannou M, Peng L, Catapano CV, Rocchi P. Katsogiannou M, et al. Among authors: rocchi p. Curr Cancer Drug Targets. 2011 Oct;11(8):954-65. doi: 10.2174/156800911797264770. Curr Cancer Drug Targets. 2011. PMID: 21861840 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

180 results

Search Page